Clinical Trial Detail

NCT ID NCT02872714
Title A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

transitional cell carcinoma



Age Groups: adult senior

Additional content available in CKB BOOST